Medication for Neuroticism? Why a Personality Trait Is Not Treated Like a Diagnosis
Updated: Oct 8
Author: Ukrainian Psychological Hub · Published: September 30, 2026 · Editorial Policy
There is no standard medication prescribed specifically to treat neuroticism as a Big Five personality trait. Neuroticism is a continuous personality dimension, not a psychiatric diagnosis. A clinician may prescribe medication for a diagnosable condition or a clinically significant symptom pattern that happens to occur in a person who is high in neuroticism, but the treatment target is the condition or symptom pattern—not a personality-test score.
That distinction matters because treatment studies do show that neuroticism scores can move during psychiatric care. In a placebo-controlled depression trial, paroxetine treatment was associated with a larger decrease in NEO Five-Factor Inventory neuroticism scores than placebo, even after analyses accounting for improvement in depression; see Tang et al. (2009). But this finding came from adults with moderate-to-severe major depressive disorder, using one antidepressant and one personality instrument. It does not establish paroxetine—or SSRIs as a class—as medication for neuroticism in people without that clinical context.
Other controlled evidence points in a less universal direction. A randomized placebo-controlled study of four weeks of escitalopram in 80 healthy first-degree relatives of people with major depression found no significant effect on neuroticism measured with either the NEO PI-R or the Eysenck Personality Questionnaire; see Knorr et al. (2012). The scientifically defensible conclusion is therefore more specific than either “antidepressants change personality” or “medication cannot affect personality”: some treatments can coincide with measurable personality change in some populations, while the size, mechanism, persistence, and clinical meaning of that change depend on the condition, intervention, instrument, and study design.
Medication for Neuroticism? The Short Answer
If the question is “What drug treats a high Big Five neuroticism score?”, the answer is that a high score by itself is not a medication indication. The National Institute of Mental Health overview of mental health medications describes psychiatric medications in relation to mental disorders, conditions, and symptom targets, with treatment plans individualized to a person’s clinical and medical situation. Neuroticism does not function as a standalone medication diagnosis in that framework.
If the question is “Can medication taken for depression, an anxiety disorder, OCD, or another condition also change a person’s neuroticism score?”, the answer is yes, that can occur. The evidence includes clinical trials in which personality measures changed during treatment. The interpretation, however, is not automatic. A lower score can reflect some combination of enduring trait change, relief from an acute symptomatic state, altered self-perception, changes in emotion processing, regression toward a person’s usual baseline, or ordinary measurement variability.
If the question is “Should someone with high neuroticism ask for medication?”, a personality score alone cannot answer it. A clinical decision starts with the person’s actual concerns: persistent anxiety, depression, obsessions and compulsions, panic, sleep disruption, trauma-related symptoms, severe distress, functional impairment, medication history, physical health, other drugs, and the full diagnostic picture. The broad mental-health relationship belongs to Neuroticism and Mental Health: Why the Trait Is a Transdiagnostic Risk Factor; the present article stays with the medication question.
Why Neuroticism Is Not Treated Like a Diagnosis
Neuroticism is a dimensional personality construct
In modern personality science, neuroticism describes relatively stable individual differences in the tendency to experience negative emotions and psychological distress. Lahey’s review describes the construct as a relatively stable tendency to respond with negative emotions to threat, frustration, and loss; see Lahey (2009). Everyone can be located somewhere on this dimension. Higher and lower scores describe differences of degree rather than the presence or absence of a disease.
The opposite pole is commonly called emotional stability. Some contemporary instruments use related but not identical labels. The BFI-2, for example, names the domain Negative Emotionality and gives it a specific facet structure; its development is documented by Soto and John (2017). NEO neuroticism, BFI-2 Negative Emotionality, IPIP scales, and Eysenck neuroticism are related measures, but their raw scores, item content, facet organization, norms, and score ranges are not interchangeable.
For the cluster’s foundational definition, see Neuroticism: What It Is in the Big Five Personality Model. The practical implication for medication is straightforward: a number on a personality inventory does not carry the same meaning as a disorder diagnosis, a symptom-severity scale, a medication indication, or a prescribing guideline.
A psychiatric diagnosis asks a different question
A diagnosis evaluates whether a defined clinical syndrome or pattern of dysfunction is present. The American Psychiatric Association’s DSM-5-TR overview describes DSM as a classification and diagnostic framework for mental disorders. Big Five neuroticism is used in personality research and assessment, but a high Big Five score is not itself a DSM diagnosis. For the diagnostic boundary in detail, see Is Neuroticism a Disorder? DSM-5-TR, ICD-11, and Personality Science.
The same distinction applies to the phrase “mental illness.” A dimensional personality trait can be associated with mental-health risk without becoming a mental illness. A person may score high in neuroticism and have no psychiatric disorder. Another person may score lower on a particular neuroticism measure and still meet criteria for a disorder. For the dedicated concept page, see Is Neuroticism a Mental Illness? Why a Personality Trait Is Not a Diagnosis.
Risk factor is not treatment target
Neuroticism is associated with elevated average risk for multiple forms of psychopathology, especially common internalizing problems, but the relationship is complex. Ormel et al. (2013) reviewed vulnerability, spectrum, common-cause, state, and scar explanations and concluded that neuroticism is useful as a broad nonspecific risk marker while its etiological meaning is not reducible to one pathway. A risk marker can help describe vulnerability without telling a clinician which medication, if any, a particular individual needs.
That is the key clinical translation. “High neuroticism” may prompt useful questions about stress sensitivity, worry, negative affect, coping, recurrent symptoms, or prior episodes. It does not bypass disorder-specific assessment. Treatment remains anchored to what is happening clinically.
What Psychiatric Medications Actually Treat
Psychiatric medications are prescribed for particular disorders, symptom domains, or other medically defined indications. According to the NIMH mental health medications guidance, antidepressants are used for depression and can also be prescribed for some other conditions such as anxiety; anti-anxiety medications target anxiety symptoms in specific clinical contexts; mood stabilizers, antipsychotics, stimulants, and other classes have their own uses, benefits, risks, and monitoring requirements. These classes should not be collapsed into a generic category of “drugs that lower neuroticism.”
A person high in neuroticism who also has major depressive disorder may receive an antidepressant because the depression warrants treatment. A person high in neuroticism who has generalized anxiety disorder may receive a medication because of the anxiety disorder and its symptoms. Someone with high neuroticism but no diagnosable disorder and no clinically significant symptom target is in a different situation. The personality trait alone does not supply a diagnosis or an automatic medication rationale.
This also explains why a medication can be relevant without turning neuroticism into an illness. Traits, disorders, and symptoms can coexist and interact. A treatment can improve a disorder, reduce symptoms, and perhaps shift a personality measure at the same time. Those are three separable outcomes that require three separable interpretations.
Can Antidepressants Change Neuroticism Scores? What the Evidence Shows
The paroxetine placebo-controlled trial in major depression
The most frequently cited medication study is Tang et al. (2009). Adults with moderate-to-severe major depressive disorder were randomized to paroxetine, placebo, or cognitive therapy. Personality was measured with the NEO Five-Factor Inventory and depression with the Hamilton Rating Scale for Depression. The paroxetine group reported a larger decrease in neuroticism than the placebo group, including analyses that attempted to account for improvement in depression.
The result is scientifically interesting because it argues against the simplest version of the “state effect” explanation—the idea that personality scores changed only because depressive symptoms improved. It does not, however, establish a universal pharmacological treatment for neuroticism. The sample had major depression, the medication was paroxetine, personality was self-reported, the comparison concerned a defined trial period, and the statistical separation of symptom and trait change does not turn a personality measure into an approved clinical indication.
A placebo-controlled escitalopram trial found no neuroticism effect
A useful counterweight is Knorr et al. (2012). Eighty healthy first-degree relatives of people with major depression were randomized to four weeks of escitalopram or placebo. Neuroticism was assessed using both the NEO PI-R and the Eysenck Personality Questionnaire. Escitalopram did not significantly change neuroticism compared with placebo on either instrument.
The populations and designs differ, so the studies should not be treated as a direct contradiction. One involved patients in an active major depressive episode; the other involved psychiatrically healthy people with familial risk and a shorter exposure. Together they demonstrate why a statement such as “SSRIs lower neuroticism” is too broad. Drug effects on personality measures cannot be assumed to generalize across clinical status, treatment duration, medication, or measurement system.
More recent depression research also finds personality scores can move during treatment
A more recent randomized active-comparator trial in moderate-to-severe major depression compared psilocybin therapy with escitalopram treatment and measured Five-Factor personality domains at baseline, six weeks, and six months. In the escitalopram condition, neuroticism decreased at six weeks and remained lower at six months; see Weiss et al. (2024). There were no compelling between-condition differences for most personality changes.
That study strengthens the observation that neuroticism measures can change during treatment for depression, including pharmacotherapy. It still does not isolate a medication-specific neuroticism effect in the way an inert-placebo comparison would, and it does not answer whether a person without depression should receive escitalopram for a personality trait. The clinical indication remained depression.
Intervention research is broader than medication research
The largest often-cited synthesis is the Roberts et al. (2017) systematic review and meta-analysis of 207 intervention studies. Across interventions, personality-trait measures changed over an average period of roughly 24 weeks, with emotional stability showing the largest treatment-associated change. The review included clinical interventions and multiple designs; it was not a demonstration that a particular drug should be prescribed for neuroticism.
This distinction prevents a common evidence error. “Personality traits can change during intervention” is supported. “Medication X is a validated treatment for high neuroticism” requires a much narrower evidence base: a defined population, a defined drug, a defined comparison, a validated neuroticism instrument, clinically meaningful outcomes, adequate safety assessment, persistence of effect, and a rationale for treating the trait itself. The literature does not justify skipping those steps.
Trait Change, Symptom Relief, and State Fluctuation Are Different
Trait change
Trait change means a change in the relatively enduring pattern that a personality measure is intended to capture. Demonstrating it convincingly usually requires repeated measurement, sufficient time, attention to measurement reliability, and evidence that the change is not merely the temporary reflection of an acute episode. A lower neuroticism score immediately after symptom improvement is suggestive; it is not automatically proof of durable personality change.
Mean-level personality change
Mean-level change refers to average change in a group. If the average neuroticism score in a treatment group decreases, that says something about the group distribution. It does not mean every participant changed, that everyone changed by the same amount, or that an individual with a similar baseline score should expect the group average. Group-level treatment effects are not individual predictions.
Individual change
Individual change concerns a specific person. To determine whether an individual’s shift exceeds plausible measurement error, one would need the same instrument, appropriate scoring, reliability information, and often repeated measurements. A raw-score decrease of five points cannot be called “real personality change” in the abstract because five points means different things on different scales.
State fluctuation
A state is a temporary condition. Acute sadness, anxiety, exhaustion, sleep loss, stress, illness, intoxication, withdrawal, or a severe depressive episode can affect how people experience themselves and how they answer personality items. When that state changes, a questionnaire score can move even if the person’s longer-term trait disposition changes less.
Symptom reduction
Symptom reduction means that symptoms of a disorder or problem have improved. Depression scores, panic frequency, obsessive-compulsive symptoms, trauma symptoms, sleep disturbance, or generalized worry can improve without requiring the conclusion that a Big Five trait has been “treated.” Conversely, a person’s neuroticism score could move modestly while clinically important symptoms remain. Both outcomes deserve their own measures.
Measurement and reporting effects
Personality questionnaires are not direct readings of a fixed biological quantity. They are psychometric instruments based on responses to items. Current mood, self-concept, interpretation of items, response style, and context can influence answers. This does not make personality assessment invalid; it means the result must be interpreted through the instrument’s design and the conditions under which it was administered.
Why Depression and Anxiety Complicate the Meaning of a Neuroticism Score
Neuroticism and common mental disorders are statistically entangled. Neuroticism can precede later symptoms and function as a vulnerability marker; symptoms can also influence personality reports; shared causes can contribute to both; and persistent episodes may produce longer-lasting change. Ormel et al. (2013) emphasize that several explanatory models can operate at once.
Clinical reviews make the same bidirectional caution. In an overview focused on anxiety and related disorders, Stein et al. (2021) describe neuroticism as strongly associated with anxiety while noting that clinicians should keep possible bidirectional influences between personality and anxiety outcomes in mind. They also discuss psychological interventions that may reduce negative emotionality, while stating that more research is needed before Big Five traits can routinely guide personalized treatment recommendations.
For medication research this means that a change in a neuroticism score during treatment is an outcome to interpret, not a shortcut around the disorder. If depression resolves and neuroticism falls, multiple processes may be involved. If neuroticism remains high while depression remits, that does not mean the treatment failed. The clinical target and the personality measure are related but separable.
Does a High Neuroticism Score Mean You Need Medication?
No universal neuroticism score implies a need for medication. A “high score” exists only inside a particular measurement system. The NEO PI-R, NEO-FFI, BFI-2 Negative Emotionality scale, IPIP measures, Eysenck instruments, and shorter online questionnaires differ in items, scoring, reliability, and reference samples. A percentile refers to a comparison with a norm group; a raw score has meaning only within the scale that produced it.
A high score can still be useful information. It may describe a person who tends to experience more worry, sadness, irritability, self-consciousness, stress sensitivity, or emotional volatility, depending on the instrument and its facets. It may also indicate a statistical vulnerability to later distress. Neither interpretation tells us whether the person currently has a mental disorder, whether symptoms cause impairment, or whether medication benefits outweigh risks.
This is why a personality inventory should not be used as a medication screening test. If a person’s concern is “my Big Five test says I am in a high percentile,” the next question is not “which medication lowers that percentile?” The useful questions concern lived experience: What symptoms are present? How long have they lasted? How much distress or impairment is there? Are there safety concerns, physical causes, substance effects, sleep problems, medication effects, or other clinical factors? Those questions belong to clinical assessment.
Can Neuroticism Be Used to Choose an Antidepressant?
Researchers have studied whether personality predicts treatment response, but this is different from using neuroticism as a validated prescribing algorithm. Findings vary by disorder, medication, population, outcome definition, and personality measure. Some associations disappear after multivariable adjustment or fail to replicate across cohorts. A predictive association in one sample should not be converted into a general rule such as “high neuroticism means use an SSRI.”
For example, a 2024 retrospective longitudinal study of 51 untreated patients with obsessive-compulsive disorder examined Eysenck personality scores and response to 12 weeks of sertraline. Lower neuroticism was associated with treatment response in univariate analyses, while high extraversion was associated with marked response; see Zhang et al. (2024). This is a disorder-specific, retrospective study of treatment response—not evidence that neuroticism itself should be medicated or that one personality score can choose treatment for everyone.
The distinction between prediction and indication is crucial. A baseline trait may correlate with how a treated disorder responds. That does not make the trait the disease being treated. Similarly, genetic or biomarker associations with treatment response do not turn neuroticism into a biological diagnosis or permit reliable individual prediction without validated clinical tools.
What About SSRIs, SNRIs, Benzodiazepines, and Other Psychiatric Drugs?
SSRIs and SNRIs
SSRIs and SNRIs are antidepressant classes used for depression and several anxiety-related conditions. They are not a category of “neuroticism medication.” A person taking one of these drugs for a clinical condition may show changes in distress, anxiety, mood, emotional processing, and sometimes personality scores. The indication, dose, duration, side-effect monitoring, and discontinuation plan are medical questions tied to the person’s condition and health context.
Benzodiazepines and other anti-anxiety medications
A medication that reduces acute anxiety is not thereby treating neuroticism. Anxiety can be a transient emotion, a symptom, a trait-like tendency, or part of a disorder. Benzodiazepines, buspirone, beta-blockers, and antidepressants have different roles and risk profiles in anxiety care; the NIMH medication overview emphasizes that medication choice depends on the clinical situation and that some drugs, including benzodiazepines, have important tolerance, dependence, and withdrawal considerations.
Mood stabilizers, antipsychotics, stimulants, and other classes
These medications have their own clinical indications and safety requirements. They should not be repurposed conceptually as ways to change a broad personality dimension. A person may have both high neuroticism and a condition for which one of these medications is indicated, but that coexistence does not establish a direct neuroticism treatment.
When Medication May Be Relevant for Someone High in Neuroticism
Medication may be relevant when a person also has a condition or symptom pattern for which pharmacotherapy is clinically appropriate. Common examples include depressive disorders and some anxiety-related disorders, but the relevant diagnosis, severity, prior treatment, preferences, medical history, pregnancy status when applicable, drug interactions, age, substance use, and side-effect profile all matter. A trait score does not replace that assessment.
Neuroticism can still contribute context. A person who tends to experience intense negative affect may notice side effects more strongly, worry more about symptoms, or have more recurrent distress. Another person with the same trait score may function well and never need psychiatric medication. The trait can describe a vulnerability pattern without determining a treatment path.
In clinical research, neuroticism also sometimes predicts course, relapse, or treatment response. Those group-level associations can help generate hypotheses and may eventually contribute to more personalized care. At present they should be interpreted as research evidence rather than a standalone prescription rule.
What If the Main Problem Is Worry, Rumination, Irritability, or Stress Sensitivity?
These experiences can be related to neuroticism, but they do not all mean the same thing. Worry may be an everyday cognitive habit, a manifestation of acute stress, or part of generalized anxiety disorder. Rumination can accompany depression and other forms of distress. Irritability has many psychological and medical contexts. Stress sensitivity may be trait-like, situational, or intensified by sleep deprivation, illness, substance use, or life events.
The useful move is to identify the actual pattern rather than treating the umbrella trait label. Frequency, duration, triggers, avoidance, impairment, sleep, physical symptoms, relationships, work or school functioning, and co-occurring symptoms help determine whether the issue is best understood as a personality tendency, a state reaction, a treatable clinical syndrome, or some combination.
This is also why “I want a pill to make me less neurotic” is clinically underspecified. The same sentence can conceal very different needs: panic attacks, persistent generalized worry, major depression, obsessive-compulsive symptoms, trauma-related hyperarousal, severe insomnia, medication side effects, situational stress, or discomfort with a personality-test label. Each requires a different assessment pathway.
Can Neuroticism Change Without Medication?
For the psychotherapy evidence and the distinction between trait change and symptom relief, see Therapy for High Neuroticism: What Treatment Can and Cannot Change.
Yes. Personality is relatively stable, but relative stability is not immutability. Longitudinal research shows mean-level personality development across the lifespan, and intervention research shows measurable changes over shorter periods. The Roberts et al. (2017) meta-analysis found intervention-associated personality change across a broad literature, with emotional stability showing the largest average treatment-associated shift.
That evidence does not imply that everyone should try to lower neuroticism. It also does not mean every therapeutic improvement is personality change. Psychological treatment can target emotion regulation, avoidance, worry, rumination, coping, or disorder-specific symptoms without defining the person’s trait as a disease. Lifestyle and environmental changes can alter stress exposure and emotional functioning without constituting a “cure.”
The cluster therefore separates the broad question of personality malleability from the medication question. NTM-120 owns medication-specific search intent. The broader evidence on whether neuroticism changes across development and intervention belongs to the dedicated change pillar, while therapy-specific methods belong to their own intervention pages. This prevents one medication article from becoming a generic treatment guide.
How to Interpret a Neuroticism Score That Falls During Treatment
Use the same instrument
A pre-treatment NEO-FFI score should be compared with a follow-up NEO-FFI score scored the same way. It should not be treated as directly equivalent to a BFI-2 Negative Emotionality score, an IPIP score, or an Eysenck neuroticism score. Different instruments operationalize the broad domain differently.
Look at timing
A score measured during an acute depressive or anxious episode may differ from a score after symptoms remit. A follow-up measured only days later may reflect a different mixture of state and trait than a follow-up months later. Persistence across repeated assessments gives stronger evidence of enduring change than a single post-treatment measurement.
Separate the clinical outcome from the personality outcome
If a person is being treated for depression, the central clinical outcome is whether depressive symptoms, functioning, safety, and quality of life improve—not whether a Big Five percentile moves. Personality measures may add useful information, but they should not displace the disorder-specific outcome for which treatment was initiated.
Consider reliable change and norms
A numerical difference is not automatically a meaningful difference. Interpretation should consider the scale’s reliability, measurement error, scoring method, and normative frame. Percentiles can also change when the comparison group changes. A raw score, T-score, percentile, or stanine is never universally “high” outside the instrument and population that define it.
What Medication Research Does Not Prove
It does not prove that neuroticism is a serotonin deficiency, dopamine problem, inflammatory disease, or other single biological disorder. Medication studies manipulate biological systems, but an observed change in a questionnaire score does not identify the biological essence of a multidimensional personality trait. Neuroticism is influenced by many genetic, developmental, environmental, social, cognitive, and state-related processes.
It does not prove that everyone high in neuroticism benefits from an antidepressant. Trials of antidepressants in major depression test treatment in people with depression. Trials in anxiety disorders test anxiety treatment. Findings about changes in personality outcomes inside those trials cannot simply be exported to healthy people who dislike a personality score.
It does not prove that symptom relief is “only personality change.” Even when statistical mediation analyses link changes in neuroticism and symptoms, mediation in one trial is not a complete causal model of depression or anxiety. Both constructs can change together because treatment affects overlapping processes.
It does not prove that personality is fixed when a particular drug has no effect. The null escitalopram finding in healthy relatives after four weeks does not mean neuroticism can never change; it means that study did not detect the hypothesized drug effect under those conditions.
Should You Start, Change, or Stop Medication Because of Neuroticism?
A Big Five result should not be used by itself to start, switch, increase, decrease, or stop a psychiatric medication. Medication decisions depend on the condition being treated, current symptoms, benefits, side effects, duration of treatment, relapse history, other medications, medical conditions, and clinician-guided risk assessment.
The NIMH guidance on mental health medications specifically advises people not to stop prescribed medication without help from a health care provider. Abrupt changes can be clinically important for several medication classes. If a person believes a medication is changing emotional range, personality, anxiety, sleep, libido, energy, or cognition, that experience is worth discussing with the prescriber rather than translating it into an unsupervised dose change.
The same rule applies in the other direction. A person should not seek a prescription solely to move a neuroticism percentile. If distress is substantial, professional assessment can identify whether there is a disorder, a symptom target, a situational problem, a medication effect, a physical-health contributor, or another issue that deserves care.
A Better Way to Frame the Question
Instead of asking “What medication treats neuroticism?”, ask what problem you want treatment to change. Is it persistent anxiety? Recurrent depression? Panic attacks? Obsessions and compulsions? Trauma-related symptoms? Sleep disruption? Severe rumination? Emotional reactivity? Functional impairment? These are clinically interpretable targets.
Then ask whether the target is a transient state, a recurring symptom pattern, a diagnosed condition, or a broad trait tendency. If a medication is appropriate, it is chosen in relation to the clinical target. If a personality measure changes during successful treatment, that can be tracked as a meaningful secondary outcome without redefining the trait as a disease.
This framing preserves both sides of the evidence: neuroticism matters for mental health, and neuroticism is not itself a psychiatric diagnosis. It also makes sense of apparently conflicting studies. A medication can alter neuroticism scores in one clinical sample, fail to alter them in another population, and still be appropriately prescribed for a disorder in both research and practice.
Frequently Asked Questions
Is there a medication specifically for neuroticism?
There is no standard medication prescribed specifically for Big Five neuroticism as a standalone trait. Psychiatric medications are used for diagnosable conditions or clinically meaningful symptom targets. A person’s neuroticism level may provide context, but it is not itself a medication indication.
Do antidepressants lower neuroticism?
Some antidepressant studies have reported decreases in neuroticism scores. The 2009 paroxetine placebo-controlled depression trial found a larger decrease than placebo, while a 2012 escitalopram placebo-controlled trial in healthy first-degree relatives found no significant neuroticism effect. The result depends on population, drug, duration, clinical state, and instrument; it should not be generalized into a class-wide treatment claim.
Can an SSRI change my personality?
Personality measures can change during SSRI treatment, particularly in people being treated for depression, but “change my personality” is much broader than a shift in one neuroticism score. Studies measure specific domains with specific instruments. Reported changes can reflect enduring trait change, symptom improvement, state change, or overlapping processes. Individual experience also varies.
Can anti-anxiety medication treat high neuroticism?
Anti-anxiety medication can be used for particular anxiety symptoms or disorders when clinically appropriate. High neuroticism is not the same construct as anxiety and is not a diagnosis. Reducing anxiety may also change how a person answers neuroticism items, but that does not make the trait the medication target.
Is high neuroticism a psychiatric disorder?
No. High neuroticism describes a position on a continuous personality dimension. It is associated with higher average risk for several mental-health problems, but risk, symptoms, and diagnosis are different. See Is Neuroticism a Disorder? DSM-5-TR, ICD-11, and Personality Science.
Does a high neuroticism percentile mean I need treatment?
No. A percentile means that a score is high relative to a particular reference sample on a particular instrument. It does not diagnose a disorder or establish medical necessity. Treatment decisions depend on distress, impairment, symptoms, diagnosis when present, risks, preferences, and the broader clinical picture.
If my neuroticism score falls after medication, does that prove my trait changed?
Not by itself. A more convincing inference would consider the same instrument across time, measurement reliability, symptom change, the timing of assessment, and whether the score remains different after the acute clinical state has stabilized. A single before-and-after score can mix trait change with state and measurement effects.
Can neuroticism be cured?
“Cure” is the wrong clinical category for a normal-range personality dimension. Neuroticism can change, and people can learn ways of responding to stress and negative emotion that improve functioning and well-being. A trait is not a disease that becomes present or absent after treatment.
Can neuroticism predict which antidepressant will work for me?
Research has examined personality as a predictor of treatment response, but findings are condition- and study-specific and do not provide a universal prescribing rule. A personality score should not be used on its own to select an antidepressant.
What should I do if I am taking medication and feel emotionally different?
Describe the change to the prescribing clinician in concrete terms—mood, anxiety, emotional intensity, sleep, energy, motivation, cognition, side effects, functioning, and timing relative to dose changes. Do not use a personality score as the sole basis for altering a prescription, and do not stop prescribed medication abruptly without medical guidance.
Related Articles
Neuroticism: What It Is in the Big Five Personality Model — the core definition of neuroticism as a dimensional personality construct.
Is Neuroticism a Mental Illness? Why a Personality Trait Is Not a Diagnosis — the direct boundary between personality variation and mental illness.
Is Neuroticism a Disorder? DSM-5-TR, ICD-11, and Personality Science — the diagnostic-classification boundary and the distinction from pathological trait models.
Neuroticism and Mental Health: Why the Trait Is a Transdiagnostic Risk Factor — evidence on broad statistical vulnerability across mental-health outcomes.
References
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR): overview and resources. APA
Knorr, U., Vinberg, M., Mortensen, E. L., Winkel, P., Gluud, C., Wetterslev, J., Gether, U., & Kessing, L. V. (2012). Effect of chronic escitalopram versus placebo on personality traits in healthy first-degree relatives of patients with depression: A randomized trial. PLOS ONE, 7(2), e31980. https://doi.org/10.1371/journal.pone.0031980
Lahey, B. B. (2009). Public health significance of neuroticism. American Psychologist, 64(4), 241–256. https://doi.org/10.1037/a0015309
National Institute of Mental Health. Mental Health Medications. NIMH
Ormel, J., Jeronimus, B. F., Kotov, R., Riese, H., Bos, E. H., Hankin, B., Rosmalen, J. G. M., & Oldehinkel, A. J. (2013). Neuroticism and common mental disorders: Meaning and utility of a complex relationship. Clinical Psychology Review, 33(5), 686–697. https://doi.org/10.1016/j.cpr.2013.04.003
Roberts, B. W., Luo, J., Briley, D. A., Chow, P. I., Su, R., & Hill, P. L. (2017). A systematic review of personality trait change through intervention. Psychological Bulletin, 143(2), 117–141. https://doi.org/10.1037/bul0000088
Soto, C. J., & John, O. P. (2017). The next Big Five Inventory (BFI-2): Developing and assessing a hierarchical model with 15 facets to enhance bandwidth, fidelity, and predictive power. Journal of Personality and Social Psychology, 113(1), 117–143. https://doi.org/10.1037/pspp0000096
Stein, D. J., Craske, M. G., Rothbaum, B. O., Chamberlain, S. R., Fineberg, N. A., Choi, K. W., de Jonge, P., Baldwin, D. S., & Maj, M. (2021). The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management. World Psychiatry, 20(3), 336–356. https://doi.org/10.1002/wps.20919
Tang, T. Z., DeRubeis, R. J., Hollon, S. D., Amsterdam, J., Shelton, R., & Schalet, B. (2009). Personality change during depression treatment: A placebo-controlled trial. Archives of General Psychiatry, 66(12), 1322–1330. https://doi.org/10.1001/archgenpsychiatry.2009.166
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2024). Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychological Medicine, 54(1), 178–192. https://doi.org/10.1017/S0033291723001514
Zhang, J., Zhong, H., Zhang, Y., Yin, J., Song, X., Ye, K., Song, Z., Lai, S., Zhong, S., Wang, Z., & Jia, Y. (2024). Personality traits as predictors for treatment response to sertraline among unmedicated obsessive-compulsive disorder: A 12-weeks retrospective longitudinal study. Journal of Psychiatric Research. https://doi.org/10.1016/j.jpsychires.2023.12.021